{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(15)"],"submitter":["Nguyen KA"],"pubmed_abstract":["Chimeric antigen receptor (CAR) T cells effectively treat B cell malignancies. However, CAR-T cells cause inflammatory toxicities such as cytokine release syndrome (CRS), which is in contrast to T cell receptor (TCR)-engineered T cells against various antigens that historically have rarely been associated with CRS. To study whether and how differences in receptor types affect the propensity for eliciting inflammatory responses in a model system wherein TCR and CAR target equalized sources of clinically relevant antigen, we discovered a CD22-specific TCR and compared it to CD22 CAR. Both CD22 TCR-T and CD22 CAR-T cells eradicated leukemia in xenografts, but only CD22 CAR-T cells induced dose-dependent systemic inflammation. Compared to TCR-T cells, CAR-T cells disproportionately upregulated"],"journal":["Science advances"],"pagination":["eadq4297"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11980841"],"repository":["biostudies-literature"],"pubmed_title":["CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses."],"pmcid":["PMC11980841"],"pubmed_authors":["Rae Z","Davies JS","Draper LM","Meyer TJ","Ishii K","Zhang L","Hinrichs CS","Taylor N","Achar SR","Liu Z","McIntosh CP","Norberg SM","Kelly MC","Nguyen KA","Altan-Bonnet G","Wu X"],"additional_accession":[]},"is_claimable":false,"name":"CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses.","description":"Chimeric antigen receptor (CAR) T cells effectively treat B cell malignancies. However, CAR-T cells cause inflammatory toxicities such as cytokine release syndrome (CRS), which is in contrast to T cell receptor (TCR)-engineered T cells against various antigens that historically have rarely been associated with CRS. To study whether and how differences in receptor types affect the propensity for eliciting inflammatory responses in a model system wherein TCR and CAR target equalized sources of clinically relevant antigen, we discovered a CD22-specific TCR and compared it to CD22 CAR. Both CD22 TCR-T and CD22 CAR-T cells eradicated leukemia in xenografts, but only CD22 CAR-T cells induced dose-dependent systemic inflammation. Compared to TCR-T cells, CAR-T cells disproportionately upregulated","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-02T10:08:30.382Z","creation":"2026-05-26T03:06:28.645Z"},"accession":"S-EPMC11980841","cross_references":{"pubmed":["40203088"],"doi":["10.1126/sciadv.adq4297"]}}